New therapeutic agents marketed in 2025: Part 2
Tracking # 20-1384357
$99999.00
There are no ratings for this course
Learn more Educator AMERICAN PHARMACISTS ASSOCIATION
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
0202-0000-26-264-H01-P The FDA approved 46 new drugs in 2025. Seven new therapeutic agents are considered in this review, the second in a two-part series of articles on new therapeutic agents approved in 2025. These new drugs include zoliflodacin (Nuzolvence--Entasis Therapeutics/Innoviva Specialty Therapeutics), lerodalcibep-liga (Lerochol--LIB Therapeutics), etripamil (Cardamyst--Milestone Pharmaceuticals), aficamten (Myqorzo--Cytokinetics), depemokimab-ulaa (Exdensur--GSK), remibrutinib (Rhapsido--Novartis), tradipitant (Nereus--Vanda Pharmaceuticals).
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
1h
General